Noonan syndrome and RASopathies: Clinical features, diagnosis and management

다국어 초록 (Multilingual Abstract)

Noonan syndrome (NS) and NS-related disorders (cardio-facio-cutaneous syndrome, Costello syndrome, NS with multiple lentigines, or LEOPARD [lentigines, ECG conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal geni-talia, retardation of growth and sensory neural deafness] syndrome) are collectively named as RASopathies. Clinical presenta-tions are similar, featured with typical facial features, short stature, intellectual disability, ectodermal abnormalities, congenital heart diseases, chest & skeletal deformity and delayed puberty. During past decades, molecular etiologies of RASopathies have been growingly discovered. The functional perturbations of the RAS-mitogen-activated protein kinase pathway are re-sulted from the mutation of more than 20 genes (PTPN11, SOS1, RAF1, SHOC2, BRAF, KRAS, NRAS, HRAS, MEK1, MEK2, CBL, SOS2, RIT, RRAS, RASA2, SPRY1, LZTR1, MAP3K8, MYST4, A2ML1, RRAS2). The PTPN11 (40-50%), SOS1 (10-20%), RAF1 (3-17%), and RIT1 (5-9%) mutations are common in NS patients. In this review, the constellation of overlapping clinical features of RASopathies will be described based on genotype as well as their differential diagnostic points and management.

참고문헌 (Reference)

1 Tajan M, "The RASopathy family : consequences of germline activation of the RAS/MAPK pathway" 39 : 676-700, 2018

2 Tidyman WE, "The RASopathies : developmental syndromes of Ras/MAPK pathway dysregulation" 19 : 230-236, 2009

3 Aoki Y, "The RAS/MAPK syndromes : novel roles of the RAS pathway in human genetic disorders" 29 : 992-1006, 2008

4 Lee BH, "Spectrum of mutations in Noonan syndrome and their correlation with phenotypes" 159 : 1029-1035, 2011

5 Dentici ML, "Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations" 17 : 733-740, 2009

6 Tartaglia M, "Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia" 34 : 148-150, 2003

7 Kirk JM, "Short stature in Noonan syndrome : response to growth hormone therapy" 84 : 440-443, 2001

8 Gureasko J, "Role of the histone domain in the autoinhibition and activation of the Ras activator Son of Sevenless" 107 : 3430-3435, 2010

9 Tamburrino F, "Response to long-term growth hormone therapy in patients affected by RASopathies and growth hormone deficiency: patterns of growth, puberty and final height data" 167A : 2786-2794, 2015

10 Raaijmakers R, "Response to growth hormone treatment and final height in Noonan syndrome in a large cohort of patients in the KIGS database" 21 : 267-273, 2008

11 Choi JH, "Response to growth hormone therapy in children with Noonan syndrome : correlation with or without PTPN11 gene mutation" 77 : 388-393, 2012

12 Ko JM, "PTPN11, SOS1, KRAS, and RAF1gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome" 53 : 999-1006, 2008

13 Tartaglia M, "PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity" 70 : 1555-1563, 2002

14 Romano AA, "Noonan syndrome: clinical features, diagnosis, and management guidelines" 126 : 746-759, 2010

15 Jorge AA, "Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS/MAPK pathway" 71 : 185-193, 2009

16 Tartaglia M, "Noonan syndrome and related disorders : genetics and pathogenesis" 6 : 45-68, 2005

17 Roberts AE, "Noonan syndrome" 381 : 333-342, 2013

18 Stofega MR, "Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GHpromoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B" 14 : 1338-1350, 2000

19 Cordeddu V, "Mutation of SHOC2 promotes aberrant protein Nmyristoylation and causes Noonan-like syndrome with loose anagen hair" 41 : 1022-1026, 2009

20 Schulz AL, "Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome" 73 : 62-70, 2008

21 Komatsuzaki S, "Mutation analysis of the SHOC2 gene in Noonan-like syndrome and in hematologic malignancies" 55 : 801-809, 2010

22 Narumi Y, "Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome:overlapping clinical manifestations with Costello syndrome" 143A : 799-807, 2007

23 Kobayashi T, "Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation" 31 : 284-294, 2010

24 Kavamura MI, "Management of genetic syndromes" Wiley-Blackwell 149-156, 2010

25 Kerr B, "Management of genetic syndromes" Wiley-Blackwell 211-225, 2010

26 Noordam C, "Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11" 159 : 203-208, 2008

27 Osio D, "Improved final height with long-term growth hormone treatment in Noonan syndrome" 94 : 1232-1237, 2005

28 Romano AA, "Growth response, near-adult height, and patterns of growth and puberty in patients with Noonan syndrome treated with growth hormone" 94 : 2338-2344, 2009

29 Digilio MC, "Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene" 71 : 389-394, 2002

30 Niihori T, "Germline-activating RRAS2 mutations cause Noonan syndrome" 104 : 1233-1240, 2019

31 Roberts AE, "Germline gain-of-function mutations in SOS1 cause Noonan syndrome" 39 : 70-74, 2007

32 Razzaque MA, "Germline gain-of-function mutations in RAF1 cause Noonan syndrome" 39 : 1013-1017, 2007

33 Niihori T, "Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome" 38 : 294-296, 2006

34 Sarkozy A, "Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum" 30 : 695-702, 2009

35 Zenker M, "Genotype-phenotype correlations in Noonan syndrome" 144 : 368-374, 2004

36 Kerr B, "Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases" 43 : 401-405, 2006

37 Kouz K, "Genotype and phenotype in patients with Noonan syndrome and a RIT1 mutation" 18 : 1226-1234, 2016

38 Tartaglia M, "Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome" 39 : 75-79, 2007

39 Pandit B, "Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy" 39 : 1007-1012, 2007

40 Zenker M, "Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations" 44 : 131-135, 2007

41 van der Burgt I, "Clinical and molecular studies in a large Dutch family with Noonan syndrome" 53 : 187-191, 1994

42 Nava C, "Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway : genotype-phenotype relationships and overlap with Costello syndrome" 44 : 763-771, 2007

43 Jongmans MC, "Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation" 19 : 870-874, 2011

44 Padidela R, "Abnormal growth in Noonan syndrome : genetic and endocrine features and optimal treatment" 70 : 129-136, 2008

45 Cirstea IC, "A restricted spectrum of NRAS mutations causes Noonan syndrome" 42 : 27-29, 2010